Skip to content

Study · Randomized controlled trial · n = 84 · 2006

5 results

A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis.

Vande Walle JG, Bogaert GA, Mattsson S, Schurmans T, Hoebeke P, Deboe V, Norgaard JP

BJU international1 Mar 2006Cited by 46 (Europe PMC)

PMID16469035 (opens in a new tab)DOI10.1111/j.1464-410x.2006.05999.x (opens in a new tab)PepBankPUB-16469035
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In hydrated children with enuresis, all 72 desmopressin recipients responded pharmacodynamically, while the placebo group of 12 showed no urinary-output change.

    In plain wordsIn hydrated children with bedwetting, all 72 desmopressin recipients responded, while 12 placebo recipients showed no urine-output change.

    Peptide
    Desmopressin
    Outcome
    IncreasePharmacodynamic response
    Study

    n = 84

    Comparator
    Placebo
    Outcome group
    Urine Production · Kidney and urinary
    Studied dose
    30, 60, 120, 240, 360 or 480 microg · oral lyophilisateAs given in this study (human).

    Measurements

    Participants with pharmacodynamic response
    72 participants
    All desmopressin recipients

    Source sentences

    Summary
    All 72 participants receiving desmopressin had a pharmacodynamic response to the drug, while there was no change in urinary output in the 12 placebo-treated patients.
    3 context sentences
    Summary · context
    Children with PNE (mean three or more wet nights/week), aged 6-12 years, were randomized into a double-blind, placebo-controlled study.
    Summary · context
    An overhydration technique was used before dosing to suppress endogenous vasopressin production and thereby ensure that any antidiuresis could be attributed to treatment.
    Summary · context
    Dosing with desmopressin or placebo occurred when urinary production was >0.13 mL/min/kg.
  2. 02HumanRandomized controlled trialActivity measurement

    In children with enuresis, desmopressin dose related to duration of action, although the three highest-dose groups had similar results.

    In plain wordsIn children with bedwetting, desmopressin dose related to action duration, although the three highest doses had similar results.

    Peptide
    Desmopressin
    Outcome
    Direction not reportedDose-dependent duration of action
    Study

    n = 72

    Outcome group
    Urine Production · Kidney and urinary
    Studied dose
    30, 60, 120, 240, 360 or 480 microg · oral lyophilisateAs given in this study (human).

    Source sentences

    Summary
    There was a clear relationship between desmopressin dose and duration of action and osmolality during action, although the three highest-dose groups had similar results.
    3 context sentences
    Summary · context
    Children with PNE (mean three or more wet nights/week), aged 6-12 years, were randomized into a double-blind, placebo-controlled study.
    Summary · context
    An overhydration technique was used before dosing to suppress endogenous vasopressin production and thereby ensure that any antidiuresis could be attributed to treatment.
    Summary · context
    Dosing with desmopressin or placebo occurred when urinary production was >0.13 mL/min/kg.
  3. 03HumanRandomized controlled trialActivity measurement

    In children with enuresis, desmopressin dose related to osmolality during action, although the three highest-dose groups had similar results.

    In plain wordsIn children with bedwetting, desmopressin dose related to urine concentration, although the three highest doses had similar results.

    Peptide
    Desmopressin
    Outcome
    Direction not reportedDose-dependent urinary osmolality
    Study

    n = 72

    Outcome group
    Urine Production · Kidney and urinary
    Studied dose
    30, 60, 120, 240, 360 or 480 microg · oral lyophilisateAs given in this study (human).

    Source sentences

    Summary
    There was a clear relationship between desmopressin dose and duration of action and osmolality during action, although the three highest-dose groups had similar results.
    3 context sentences
    Summary · context
    Children with PNE (mean three or more wet nights/week), aged 6-12 years, were randomized into a double-blind, placebo-controlled study.
    Summary · context
    An overhydration technique was used before dosing to suppress endogenous vasopressin production and thereby ensure that any antidiuresis could be attributed to treatment.
    Summary · context
    Dosing with desmopressin or placebo occurred when urinary production was >0.13 mL/min/kg.
  4. 04HumanRandomized controlled trialActivity measurement

    In children with enuresis, mean desmopressin action duration at the lowest osmolality threshold ranged from 3.6-10.6 h according to dose.

    In plain wordsIn children with bedwetting, desmopressin acted for 3.6-10.6 h at the lowest urine-concentration threshold, depending on dose.

    Peptide
    Desmopressin
    Outcome
    Not applicableDuration above lowest osmolality threshold
    Study

    n = 72

    Outcome group
    Urine Production · Kidney and urinary
    Studied dose
    30, 60, 120, 240, 360 or 480 microg · oral lyophilisateAs given in this study (human).

    Measurements

    Mean duration of action, lowest osmolality threshold
    3.6 to 10.6 h
    Across dose groups, 30-480 microg

    Source sentences

    Summary
    The mean duration of action of desmopressin at the lowest osmolality threshold level was 3.6-10.6 h, according to dose; for the highest threshold, the values were 1.3-8.6 h.
    3 context sentences
    Summary · context
    Children with PNE (mean three or more wet nights/week), aged 6-12 years, were randomized into a double-blind, placebo-controlled study.
    Summary · context
    An overhydration technique was used before dosing to suppress endogenous vasopressin production and thereby ensure that any antidiuresis could be attributed to treatment.
    Summary · context
    Dosing with desmopressin or placebo occurred when urinary production was >0.13 mL/min/kg.
  5. 05HumanRandomized controlled trialActivity measurement

    In children with enuresis, mean desmopressin action duration at the highest osmolality threshold ranged from 1.3-8.6 h.

    In plain wordsIn children with bedwetting, desmopressin acted for 1.3-8.6 h at the highest urine-concentration threshold.

    Peptide
    Desmopressin
    Outcome
    Not applicableDuration above highest osmolality threshold
    Study

    n = 72

    Outcome group
    Urine Production · Kidney and urinary
    Studied dose
    30, 60, 120, 240, 360 or 480 microg · oral lyophilisateAs given in this study (human).

    Measurements

    Mean duration of action, highest osmolality threshold
    1.3 to 8.6 h
    Across dose groups, 30-480 microg

    Source sentences

    Summary
    The mean duration of action of desmopressin at the lowest osmolality threshold level was 3.6-10.6 h, according to dose; for the highest threshold, the values were 1.3-8.6 h.
    3 context sentences
    Summary · context
    Children with PNE (mean three or more wet nights/week), aged 6-12 years, were randomized into a double-blind, placebo-controlled study.
    Summary · context
    An overhydration technique was used before dosing to suppress endogenous vasopressin production and thereby ensure that any antidiuresis could be attributed to treatment.
    Summary · context
    Dosing with desmopressin or placebo occurred when urinary production was >0.13 mL/min/kg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.